RET and non-small cell lung carcinoma: In addition, a post hoc analysis of the LIBRETTO-001 and LIBRETTO-201 trials of selpercatinib in RET fusion-positive NSCLC found that the incidence of BrMs remained at 0% for up to 36 months in 30 patients without BrMs at baseline [91].